BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 36572596)

  • 1. The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R): Real-World Data on Stage III Non-Small Cell Lung Cancer Patients Treated With Curative Chemoradiation.
    Dieleman E; van der Woude L; van Os R; van Bockel L; Coremans I; van Es C; De Jaeger K; Knol HP; Kolff W; Koppe F; Pomp J; Reymen B; Schinagl D; Spoelstra F; Tissing-Tan C; van der Voort van Zyp N; van der Wel A; Wijsman R; Dielwart M; Wiegman E; Damhuis R; Belderbos J
    Clin Lung Cancer; 2023 Mar; 24(2):130-136. PubMed ID: 36572596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Variation of Sequential versus Concurrent Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer Patients in the Netherlands and Belgium.
    Walraven I; Damhuis RA; Ten Berge MG; Rosskamp M; van Eycken L; de Ruysscher D; Belderbos JSA
    Clin Oncol (R Coll Radiol); 2017 Nov; 29(11):e177-e185. PubMed ID: 28780009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent versus sequential chemoradiotherapy for unresectable locally advanced stage III non-small cell lung cancer: Retrospective analysis in a single United Kingdom cancer centre.
    Spencer A; Williams J; Samuel R; Boon IS; Clarke K; Jain P
    Cancer Treat Res Commun; 2021; 29():100460. PubMed ID: 34598059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center.
    Shrimali RK; Nallathambi C; Saha A; Das A; Prasath S; Mahata A; Arun B; Mallick I; Achari R; Dabkara D; Thambudorai R; Chatterjee S
    Indian J Cancer; 2018; 55(2):125-133. PubMed ID: 30604722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience.
    Mertsoylu H; Köse F; Sümbül AT; Sedef AM; Doğan Ö; Besen AA; Parlak C; Fındıkçıoğlu A; Muallaoğlu S; Sezer A; Sakallı H; Özyılkan Ö
    Med Sci Monit; 2015 Mar; 21():661-6. PubMed ID: 25731741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival outcomes and predicting intracranial metastasis in stage III non-small cell lung cancer treated with definitive chemoradiation: Real-world data from a tertiary cancer center.
    Thibodeau S; Meem M; Hopman W; Sandhu S; Zalay O; Fung AS; Kartolo A; Digby GC; Al-Ghamdi S; Robinson A; Ashworth A; Owen T; Mahmud A; Tam K; Olding T; de Moraes FY
    Cancer Treat Res Commun; 2023; 36():100747. PubMed ID: 37531737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
    Taugner J; Käsmann L; Karin M; Eze C; Flörsch B; Guggenberger J; Li M; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
    Invest New Drugs; 2022 Feb; 40(1):163-171. PubMed ID: 34351518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A decade of community-based outcomes of patients treated with curative radiotherapy with or without chemotherapy for non-small cell lung cancer.
    Pramana A; Descallar J; Vinod SK
    Asia Pac J Clin Oncol; 2016 Sep; 12(3):e357-66. PubMed ID: 25155757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer.
    Bobbili P; Ryan K; DerSarkissian M; Dua A; Yee C; Duh MS; Gomez JE
    PLoS One; 2020; 15(3):e0230444. PubMed ID: 32187231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial.
    Bi N; Liang J; Zhou Z; Chen D; Fu Z; Yang X; Feng Q; Hui Z; Xiao Z; Lv J; Wang X; Zhang T; Wang X; Deng L; Wang W; Wang J; Liu L; Hu C; Wang L
    JAMA Netw Open; 2019 Dec; 2(12):e1918070. PubMed ID: 31851351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomes.
    Phernambucq EC; Hartemink KJ; Smit EF; Paul MA; Postmus PE; Comans EF; Senan S
    J Thorac Oncol; 2012 Aug; 7(8):1271-5. PubMed ID: 22659960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
    Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
    Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy.
    Chen K; Li S; Chen M; Jin Z; Sun X; Zhou S; Yang H
    BMC Cancer; 2024 Feb; 24(1):257. PubMed ID: 38395838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Efficacy and Toxicity of Concurrent Chemoradiotherapy and Durvalumab and Concurrent Chemoradiotherapy Alone for Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Metastasis.
    Abe T; Iino M; Saito S; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki YU; Miura YU; Kaira K; Kagamu H; Noda SE; Kato S
    Anticancer Res; 2023 Feb; 43(2):675-682. PubMed ID: 36697072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Outcome of concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer patients].
    Liu L; Wang X; Ji Z; Wang J; Bi N; Hui Z; Lyu J; Liang J; Zhou Z; Feng Q; Chen D; Zhang H; Xiao Z; Yin W; Wang L
    Zhonghua Zhong Liu Za Zhi; 2015 Nov; 37(11):863-7. PubMed ID: 26887520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?
    Hendriks LEL; Brouns -JWM; Amini M; Uyterlinde W; Wijsman R; Bussink J; Biesma B; Oei SB; Stigt JA; Bootsma GP; Belderbos JSA; De Ruysscher DKM; Van den Heuvel MM; Dingemans AC
    Lung Cancer; 2016 Nov; 101():68-75. PubMed ID: 27794410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of right ventricular function on prognosis in patients with stage III non-small cell lung cancer after concurrent chemoradiotherapy.
    Chen L; Huang J; Wu W; Ta S; Xie X
    Int J Cardiovasc Imaging; 2019 Jun; 35(6):1009-1017. PubMed ID: 30941563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
    Sher DJ; Koshy M; Liptay MJ; Fidler MJ
    Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent chemoradiotherapy versus radiotherapy alone after induction chemoimmunotherapy for stage III NSCLC patients who did not undergo surgery: a single institution retrospective study.
    Guan S; Ren K; Zhang X; Yan M; Li X; Zhao L
    Radiat Oncol; 2023 Jul; 18(1):122. PubMed ID: 37491257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System.
    Yegya-Raman N; Friedes C; Sun L; Iocolano M; Kim KN; Doucette A; Cohen RB; Robinson KW; Levin WP; Cengel KA; Lally B; Agarwal M; D'Avella CA; Marmarelis ME; Kosteva JA; Singh AP; Ciunci CA; Aggarwal C; Berman AT; Langer CJ; Feigenberg SJ
    Clin Lung Cancer; 2023 Jul; 24(5):474-482. PubMed ID: 37076396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.